RxDoctor Payments Data

James Boesiger, PA

Medical · Las Vegas, NVNPI 1104804756

Payments from drug & device makers

$2,386in general payments, 2019–2025

Across 29 payments — averaging $82.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$2K
  • Forte Bio-pharma LLC$85
  • Lilly USA, LLC$77
  • Biodelivery Sciences International, Inc.$76
  • AbbVie$64
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • plus $312 from 8 others

What the payments were for

  • Speaking & faculty fees$1,68070%
  • Food & beverage$70630%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,386 in reported general payments places this provider in the 70th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$34,257
Medicare patients
74
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl37$29,972
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen869$21,481
Xtampza ErOxycodone Myristate24$16,692
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen521$15,931
Gabapentin480$6,066
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl38$5,402
SymproicNaldemedine Tosylate11$5,010
Oxycodone Hcl352$4,721
Morphine Sulfate ErMorphine Sulfate156$3,866
Lidocaine15$2,776
Tizanidine Hcl320$2,244
Pregabalin157$1,985
Buprenorphine Hcl34$1,981
Methocarbamol111$1,255
Tramadol Hcl142$1,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$38$46,66461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 medical providers in Nevada.

Other medical in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →